Clinical trial · Interventional
Safety of Tranexamic Acid in Reducing Blood Loss Myomectomy.
Safety of Tranexamic Acid Versus Misoprostol in Reducing Blood Loss in Myomectomy.
NCT04694677CI-TRIAL-00049235unknownN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Uterine leiomyomas (fibroids) are the most common benign tumors among women . Fibroids are found in approximately 15% to 30% of women in the reproductive age group
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Myoma | Myoma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| women receiving misoprostol | Drug | — | UNRESOLVED |
| women receiving tranexamic acid | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- ACTIVE_COMPARATOR
- label
- women receiving tranexamic acid
- interventionNames
- Drug: women receiving tranexamic acid
- type
- ACTIVE_COMPARATOR
- label
- women receiving misoprostol
- interventionNames
- Drug: women receiving misoprostol
Primary outcomes (1)
- measure
- the number of women who will have less blood loss
- timeFrame
- 48 hours
- description
- how many women will have less blood loss
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 20 Years
- Maximum age
- 50 Years
Show eligibility criteria text
Inclusion Criteria: * women with myomas Exclusion Criteria: * with with malignant lesions
References
Publications (0)
Data not yet available
No reference posted for this study.